Table 1.

Patient and tumor characteristics of 518 patients undergoing neoadjuvant therapy for breast cancer.

Characteristic	N (%)
Age
<50  ≥50	261 (50%) 257 (50%)
Race
Caucasian  African-American  Other	357 (69%) 149 (29%) 12 (2%)
Clinical T stage
T1  T2  T3  T4  Unknown	59 (11%) 268 (52%) 90 (17%) 80 (16%) 21 (4%)
Histology
Ductal carcinoma  Lobular carcinoma  Inflammatory  Mixed (ductal+lobular)  Other	379 (72%) 51 (10%) 35 (7%) 37 (7%) 16 (4%)
Nuclear grade
Grade 1 (well differentiated)  Grade 2 (moderately differentiated)  Grade 3 (poorly differentiated)  Unknown	51 (10%) 170 (33%) 282 (54%) 15 (3%)
Estrogen receptor status
Positive  Negative	298 (58%) 220 (42%)
Progesterone receptor status
Positive  Negative	219 (42%) 299 (58%)
HER2-neu status
Non-amplification  Amplification	384 (74%) 134 (26%)
Clinical N status
N0  N1  N2  N3  Unknown	237 (46%) 210 (41%) 28 (5%) 14 (3%) 29 (5%)
Clinical AJCC stage
1  2A  2B  3A  3B  3C  4  Unknown	32 (6%) 177 (35%) 145 (28%) 52 (10%) 69 (13%) 12 (2%) 13 (3%) 18 (3%)
Type of neoadjuvant therapy
Chemotherapy only  Hormonal therapy	456 (88%) 62 (12%)
Type of surgery performed on primary tumor
Lumpectomy  Mastectomy	207 (40%) 311 (60%)
Pathologic complete response
Yes  No	81 (16%) 437 (84%)

AJCC = American Joint Commission on Cancer